PFENYSE$26.5869

PFIZER INC

BiotechnologyRules + LLM

Score breakdown

Valuation+16Profitability+32Sentiment+12Risk penalty-11Missing signals-1

Quality breakdown

Key fields100Profile62Conclusion86AI synthesis67Observations50

PFIZER INC (PFE) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: total assets 208,160,000,000 USD, total equity 86,476,000,000, short-term debt 2,997,000,000, long-term debt 61,641,000,000. Net cash position is approximately -63,496,000,000 USD. Self-calculated market cap is 151,851,540,000 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 62,579,000,000, gross profit 0, operating income 0, net income 7,771,000,000. Return on equity ~9.0%. Return on assets ~3.7%. Operating-cash-flow to net-income ratio is 1.51. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Current ratio is close to the minimum comfort range.; Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk.. Management commentary signal: purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement..

Profile

CompanyPFIZER INC

ExchangeNYSE

TickerPFE

CIK0000078003

SICPharmaceutical Preparations

SectorHealthcare

BusinessPharmaceuticals & Medical Research

Industry groupBiotechnology & Medical Research

IndustryBiotechnology

AI analysis

Business. PFIZER INC is classified under Healthcare / Biotechnology and appears profitable on the latest normalized snapshot.

Classification. Classification confidence is 0.81 based on rule-based classification; matched terms: clinical trial, pipeline.

Key takeaways

Observed GAAP P/E is about 19.54x.
Return on equity is about 9.0%.
Debt to equity is about 0.75x.
Management signal detected: purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.

Financial snapshot

PeriodFY2025

CurrencyUSD

Revenue$62.58B

Gross profit—

Operating income—

Net income$7.77B

R&D—

SG&A—

D&A$6.59B

SBC$799.0M

Operating cash flow$11.70B

CapEx$2.63B

Free cash flow$9.07B

Total assets$208.16B

Total liabilities$121.39B

Total equity$86.48B

Cash & equivalents$1.14B

Long-term debt$61.64B

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

————

PeriodGross %Op %Net %FCF %

————

PeriodAssetsEquityCashDebt

————

PeriodOCFCapExFCFSBC

————

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

————

PeriodGross %Op %Net %FCF %

————

PeriodAssetsEquityCashDebt

————

PeriodOCFCapExFCFSBC

————

Valuation

Market price$26.58

Market cap$151.85B

Enterprise value$215.35B

P/E19.5

Reported non-GAAP P/E—

EV/Revenue3.4

EV/Op income—

EV/OCF18.4

P/B—

P/Tangible book—

Tangible book-$16.00B

Net cash-$63.50B

Current ratio1.2

Debt/Equity0.8

ROA3.7%

ROE9.0%

Cash conversion1.5%

CapEx/Revenue4.2%

SBC/Revenue1.3%

Asset intensity0.1

Dilution ratio—

Risk assessment

Dilution riskMedium

Liquidity riskHigh

Current ratio is close to the minimum comfort range.
Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.

Industry benchmarks

Activity: Biotechnology · cohort 4 companies

MetricPFEActivity

Net margin12.4%12.4% medp25 12.4% · p75 12.4%bottom quartile

CapEx / revenue4.2%4.2% medp25 4.2% · p75 4.2%bottom quartile

Debt / equity75.0%71.3% medp25 71.3% · p75 71.3%top quartile

Observations

IR observations

Analyst estimate (TR.PriceTargetMean): Mean price target = 28.97 USD
Analyst estimate (TR.PriceTargetMedian): Median price target = 28.00 USD
Analyst estimate (TR.PriceTargetHigh): High price target = 36.00 USD
Analyst estimate (TR.PriceTargetLow): Low price target = 24.00 USD
Analyst estimate (TR.RecMean): Mean recommendation = 2.59 (1=strong buy, 5=strong sell)
Analyst estimate (TR.NumOfStrongBuy): Strong-buy count = 4.00
Analyst estimate (TR.NumOfBuy): Buy count = 9.00
Analyst estimate (TR.NumOfHold): Hold count = 16.00
Analyst estimate (TR.NumOfSell): Sell count = 2.00
Analyst estimate (TR.NumOfStrongSell): Strong-sell count = 1.00

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

SEC filingstype companyfacts · CIK 0000078003 · 664 us-gaap concepts

data.sec.gov/CIK0000078003.json

2026-04-29 08:16 UTC#44907050

Market quoteclose USD 26.58 · shares 5.71B diluted

no public URL

2026-04-29 08:17 UTC#80a84cf4

Source: analysis-pipeline (hybrid)Generated: 2026-04-29 08:17 UTCJob: 56ee57bd